does blue cross cover glp-1 Blue Shield of Mass. sees gains after years of GLP-1-related losses BCBS returns to profit after

It can take up to 18 months to see the full impact of these medications

GLP-1 Pipeline In November 2023, the FDA approved Zepbound (tirzepatide), a GLP-1 antagonist and GIP dual agonist with superior weight loss efficacy compared to its competitors

Mendes FF, Carvalho LIM, Lopes MB

In contrast, in a metanalysis of 12 randomized, double-blind, placebo-controlled trials comprising 3065 of 73 238 participants (4.2%) with diabetes who were using GLP-1 RAs at baseline, SGLT2i reduced the risk of CKD progression in participants both receiving and not receiving GLP-1 RAs [HR 0.65 (95% CI 0.460.94) versus HR 0.67 (95% CI 0.620.72)

Boland BB, Mumphrey MB, Hao Z, Townsend RL, Gill B, Oldham S, et al

Future Directions and Research Opportunities Triple Agonism and Beyond The success of dual agonism has stimulated interest in triple agonism approaches that add glucagon receptor activation to GIP and GLP-1 targeting